Sector: Health Care
Director information for GERON CORP (data for year 2026)
| Name | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| Constantine Chinoporos | 2026 Director Nominee | 59 | ["Chief Operating Officer and Chief Business Officer at Applied Therapeutics","Chief Business Officer at Albireo Pharmaceuticals","Chief Business Officer at Boston Pharmaceuticals","experience in biopharmaceutical business development","expertise in sourcing, structuring, and closing licensing and acquisition transactions","knowledge of commercial operations and healthcare-related issues"] | ["Compensation Committee"] | 2026 |
| Dawn C. Bir | Continuing Director; Former Interim President and Chief Executive Officer | 55 | ["Chief Commercial Officer of Reata Pharmaceuticals, Inc.","Vice President of Sales at Pharmacyclics LLC","Vice President of Sales & Marketing of SKY Pharmaceuticals Packaging, Inc. & Rx Pak","Various commercial and sales positions at Genentech, Inc. and Bristol Myers Squibb Company","B.S. in Biology from Binghamton University"] | ["M","C"] | 2026 |
| Elizabeth G. O'Farrell | Continuing Director | 61 | ["Significant financial, operational and corporate governance expertise","Management and leadership experience in various roles at Eli Lilly and Company","Knowledge and experience as a senior executive in a large global pharmaceutical company"] | ["C","FE"] | 2026 |
| Harout Semerjian | Continuing Director; President and Chief Executive Officer | 55 | ["Served as director of Geron","Served as President and Chief Executive Officer of GlycoMimetics, Inc.","Independent healthcare consultant at Emerge Bio Consulting","Served as President and Chief Executive Officer of Immunomedics Inc.","Executive Vice President, Chief Commercial Officer of Ipsen Pharma","Held several commercial, marketing and sales positions at Novartis Pharmaceuticals","Holds an MBA from Cornell University and Queen's University","B.S. in Biology from Lebanese American University"] | ["Biotechnology Innovation Organization"] | 2026 |
| John F. McDonald | Continuing Director | 65 | ["Vice President, Business Development and Mergers and Acquisitions at Novo Nordisk A/S","Vice President, Business Development at Biogen Inc.","Managing Director at MPM Capital LP","Business development, corporate strategy, and legal roles at various biopharmaceutical companies"] | ["M"] | 2026 |
| Patricia S. Andrews | 2026 Director Nominee | 68 | ["Chief Executive Officer of Sumitomo Pharma Oncology","Global Head of Oncology for Sumitomo Pharma","Executive Vice President and Chief Commercial Officer at Incyte Corporation","Roles at Pfizer Inc."] | ["M","Audit Committee"] | 2026 |
| Robert J. Spiegel, M.D., FACP | Continuing Director | ["Associate Professor at the Weill Cornell Medical School","Senior Advisor to Warburg Pincus","Advisor to the Israel Biotech Fund","Director of clinical research for oncology at Schering-Plough","Chief Medical Officer of PTC Therapeutics, Inc.","Senior Vice President of the Schering-Plough Research Institute","Extensive medical experience developing oncology products","Deep understanding of pharmaceutical research and development","Expertise in gaining regulatory approval for drug candidates"] | ["M"] | 2026 | |
| Susan M. Molineaux, Ph.D. | 2026 Director Nominee | 72 | ["Executive Chair of Seranova Bio Inc.","Chief Executive Officer at Para Therapeutics, Inc.","Board member of Repare Therapeutics Inc.","Chief Executive Officer, President, and board member of Calithera Biosciences, Inc.","Board member of Cyteir Therapeutics, Inc.","Board member of Theravance Biopharma, Inc.","Co-founder of Proteolix, Inc.","Senior management positions at Rigel Pharmaceuticals, Inc.","Senior management positions at Praelux, Inc.","Senior management positions at Praecis Pharmaceuticals, Inc.","Scientific Advisor to Lightstone Ventures","B.S. in biology from Smith College","Ph.D. in molecular biology from Johns Hopkins University","Completed a postdoctoral fellowship at Columbia University"] | ["AC","CC"] | 2026 |
